ONO PHARMACEUTICAL CO

🇯🇵Japan
Ownership
-
Established
1947-01-01
Employees
-
Market Cap
$7.1B
Website
https://www.ono.co.jp/

Study of ONO-1101 in Patients Scheduled for Coronary Angiography

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-11-19
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
183
Registration Number
NCT00560209
Locations
🇯🇵

Kinki Region, Kinki, Japan

Long-term Safety and Efficacy of Imidafenacin in Patients With Overactive Bladder

Phase 3
Completed
Conditions
Interventions
First Posted Date
2007-08-08
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
435
Registration Number
NCT00512785
Locations
🇯🇵

Kinki Region, Kinki, Japan

🇯🇵

Kanto Region, Kanto, Japan

Controlled Study of ONO-5046Na in Patients With Acute Respiratory Failure Associated With Community-Acquired Pneumonia

Phase 2
Completed
Conditions
Interventions
First Posted Date
2007-01-01
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
174
Registration Number
NCT00417326
Locations
🇯🇵

Chugoku Region, Chugoku, Japan

🇯🇵

Hokkaido Region, Hokkaido, Japan

🇯🇵

Hokuriku Region, Hokuriku, Japan

and more 6 locations

Study of ONO-1078 in Patients With Chronic Sinusitis

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-12-13
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
495
Registration Number
NCT00410735
Locations
🇯🇵

Chubu region, Chubu, Japan

🇯🇵

Hokuriku region, Hokuriku, Japan

🇯🇵

Kanto region, Kanto, Japan

and more 3 locations

Placebo Controlled Study of ONO2506PO in the Presence of Riluzole in Patients With Amyotrophic Lateral Sclerosis (ALS)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2006-11-23
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
420
Registration Number
NCT00403104
Locations
🇧🇪

UCL Saint-Luc, Brussels, Belgium

🇧🇪

UZ Leuven, Leuven, Belgium

🇫🇷

Hopital de la Timone, Marseille, France

and more 23 locations

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

Phase 3
Completed
Conditions
Interventions
First Posted Date
2006-08-15
Last Posted Date
2012-06-14
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
209
Registration Number
NCT00363844
Locations
🇯🇵

Kanto Region, Kanto, Japan

🇯🇵

Chubu Region, Chubu, Japan

🇯🇵

Hokkaido Region, Hokkaido, Japan

and more 5 locations

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

First Posted Date
2006-08-15
Last Posted Date
2012-06-14
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
195
Registration Number
NCT00363519
Locations
🇯🇵

Hokkaido Region, Hokkaido, Japan

🇯🇵

Chugoku Region, Chugoku, Japan

🇯🇵

Kanto Region, Kanto, Japan

and more 5 locations

Controlled Study of MK-0431/ONO-5435 in Patients With Type 2 Diabetes Mellitus

First Posted Date
2006-08-15
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
188
Registration Number
NCT00363948
Locations
🇯🇵

Chugoku Region, Chugoku, Japan

🇯🇵

Hokkaido Region, Hokkaido, Japan

🇯🇵

Hokuriku Region, Hokuriku, Japan

and more 5 locations

Pilot Study of ONO-1101 in Patients Scheduled for Multi-slice CT

Phase 2
Completed
Conditions
First Posted Date
2006-04-05
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
90
Registration Number
NCT00311038
Locations
🇯🇵

Kanto Region Facility, Kanto, Japan

🇯🇵

Hokuriku Region Facility, Hokuriku, Japan

🇯🇵

Kyusyu Region Facility, Kyusyu, Japan

Study of ONO-2506 in Patients With Acute Ischemic Stroke

Phase 2
Completed
Conditions
Interventions
First Posted Date
2005-09-29
Last Posted Date
2012-06-13
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
757
Registration Number
NCT00229177
Locations
🇯🇵

Kinki Region Facility, Kinki, Japan

🇯🇵

Chubu Region Facility, Chubu, Japan

🇯🇵

Chugoku Region Facility, Chugoku, Japan

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath